期刊
WORLD JOURNAL OF GASTROINTESTINAL SURGERY
卷 13, 期 10, 页码 1136-1148出版社
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.4240/wjgs.v13.i10.1136
关键词
Programmed cell death 1/programmed cell death ligand 1 inhibitors ; Targeted therapy; Hepatocellular carcinoma; Programmed cell death & nbsp;1 ; Programmed cell death ligand 1
资金
- CAMS Innovation Fund for Medical Science (CIFMS)
- Beijing Hope Run Special Fund of Cancer Foundation of China
Recent years have seen success in phase III trials for targeted therapeutic agents in treating advanced hepatocellular carcinoma (HCC), with immunotherapy also considered effective. However, treating advanced HCC remains a challenge, highlighting the urgent need for new treatments.
In recent years, a number of targeted therapeutic agents have achieved success in phase III trials in patients with advanced hepatocellular carcinoma (HCC), including sorafenib, lenvatinib, and regorafenib. Immunotherapy is considered to be an effective treatment for advanced HCC. Immune checkpoint inhibitors targeting programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) are important antitumor immunotherapy agents that represent breakthroughs in the treatment of advanced HCC. However, treating advanced HCC is still a great challenge, and the need for new treatments remains urgent. This review briefly summarizes the research progress in the use of PD-1/PD-L1 inhibitors combined with targeted therapy for treating HCC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据